drugset
Drugs / IMCY-0141
last change Dec 2025 re-read 9 days ago

IMCY-0141

Peptide

Developed for
relapsing-remitting multiple sclerosis
Investigated by
Imcyse SA

Trials 1

today NCT05417269 · Ph 1/2
2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05417269 Apr 2022 → May 2025 relapsing-remitting multiple sclerosis Imcyse SA Unknown No outcome recorded

Press releases naming this drug 2 releases

DateIssuerRelease
2023-09-13 Imcyse SA Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY-0141 for the Treatment of Multiple Sclerosis imcyse.com ↗
2022-04-13 Imcyse SA Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of Imotope™ IMCY-0141 for Multiple Sclerosis imcyse.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as IMCY-0141 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05417269 ↗
Modality Peptide “small synthetic peptide” NCT05417269 ↗
Route Subcutaneous “subcutaneous (SC) administration” NCT05417269 ↗